JP2022550099A5 - - Google Patents
Info
- Publication number
- JP2022550099A5 JP2022550099A5 JP2022519289A JP2022519289A JP2022550099A5 JP 2022550099 A5 JP2022550099 A5 JP 2022550099A5 JP 2022519289 A JP2022519289 A JP 2022519289A JP 2022519289 A JP2022519289 A JP 2022519289A JP 2022550099 A5 JP2022550099 A5 JP 2022550099A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cyano
- halo
- cycloalkyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025107082A JP2025138749A (ja) | 2019-09-27 | 2025-06-25 | 疾患の処置のための受容体相互作用プロテインキナーゼｉの阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962907146P | 2019-09-27 | 2019-09-27 | |
| US62/907,146 | 2019-09-27 | ||
| PCT/US2020/052789 WO2021062199A1 (en) | 2019-09-27 | 2020-09-25 | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025107082A Division JP2025138749A (ja) | 2019-09-27 | 2025-06-25 | 疾患の処置のための受容体相互作用プロテインキナーゼｉの阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022550099A JP2022550099A (ja) | 2022-11-30 |
| JP2022550099A5 true JP2022550099A5 (enExample) | 2023-09-26 |
| JP7802655B2 JP7802655B2 (ja) | 2026-01-20 |
Family
ID=75162965
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022519289A Active JP7802655B2 (ja) | 2019-09-27 | 2020-09-25 | 疾患の処置のための受容体相互作用プロテインキナーゼｉの阻害剤 |
| JP2025107082A Pending JP2025138749A (ja) | 2019-09-27 | 2025-06-25 | 疾患の処置のための受容体相互作用プロテインキナーゼｉの阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025107082A Pending JP2025138749A (ja) | 2019-09-27 | 2025-06-25 | 疾患の処置のための受容体相互作用プロテインキナーゼｉの阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11753381B2 (enExample) |
| EP (1) | EP4034530A4 (enExample) |
| JP (2) | JP7802655B2 (enExample) |
| KR (1) | KR20220072857A (enExample) |
| CN (1) | CN115605463B (enExample) |
| AU (1) | AU2020353663B2 (enExample) |
| BR (1) | BR112022005627A2 (enExample) |
| CA (1) | CA3155259A1 (enExample) |
| IL (1) | IL291665B2 (enExample) |
| MX (1) | MX2022003671A (enExample) |
| WO (1) | WO2021062199A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021046515A1 (en) | 2019-09-06 | 2021-03-11 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| IL291665B2 (en) | 2019-09-27 | 2025-07-01 | Univ Texas | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| BR112022010082A2 (pt) | 2019-11-26 | 2022-08-30 | Univ Texas | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica |
| EP4294798A1 (en) * | 2021-02-19 | 2023-12-27 | Kalvista Pharmaceuticals Limited | Factor xiia inhibitors |
| CN116444437B (zh) * | 2023-03-08 | 2025-09-16 | 曲靖师范学院 | 抗癌医药达洛鲁胺的合成方法 |
| CN121487930A (zh) * | 2023-05-10 | 2026-02-06 | 建新公司 | 作为ripk1抑制剂的异噁唑烷及其用途 |
| CN121079291A (zh) * | 2023-05-10 | 2025-12-05 | 建新公司 | 作为ripk1抑制剂的异噁唑烷及其使用 |
| WO2025165774A1 (en) * | 2024-02-01 | 2025-08-07 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| WO2026001865A1 (en) * | 2024-06-24 | 2026-01-02 | Sironax Ltd. | Rip1 modulators, preparations, and uses thereof |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU778393B2 (en) | 1999-05-12 | 2004-12-02 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
| JP2012513481A (ja) | 2008-12-23 | 2012-06-14 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | ネクロトーシスの小分子阻害剤 |
| EP2421834A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
| US8987275B2 (en) | 2010-03-16 | 2015-03-24 | Dana-Farber Cancer Institute, Inc. | Indazole compounds and their uses |
| US9643977B2 (en) | 2011-03-11 | 2017-05-09 | President And Fellows Of Harvard College | Necroptosis inhibitors and methods of use therefor |
| EP2739143B1 (en) | 2011-08-05 | 2018-07-11 | Gary A. Flynn | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
| CN102643268B (zh) | 2011-12-30 | 2014-05-21 | 沈阳药科大学 | 喹啉类及噌啉类化合物及其应用 |
| DK2810937T3 (en) | 2012-01-31 | 2017-03-13 | Daiichi Sankyo Co Ltd | PYRIDONE DERIVATIVES |
| TWI637951B (zh) | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
| KR20150118158A (ko) | 2013-02-22 | 2015-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 비시클릭 화합물 |
| SI3030549T1 (sl) | 2013-09-12 | 2019-08-30 | Janssen Biopharma, Inc. | Spojine piridazinona in njihove uporabe |
| WO2015199206A1 (ja) * | 2014-06-27 | 2015-12-30 | 塩野義製薬株式会社 | Ｔｒｐｖ４阻害活性を有する６員環誘導体 |
| CN106573006A (zh) | 2014-08-21 | 2017-04-19 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为药物的rip1激酶抑制剂杂环酰胺 |
| US10308609B2 (en) * | 2014-09-17 | 2019-06-04 | Zeno Royalties & Milestones, LLC | Bicyclic compounds |
| EP3224245B1 (en) * | 2014-12-24 | 2018-09-12 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
| ES2769031T3 (es) * | 2015-03-20 | 2020-06-24 | Pfizer | Agentes citotóxicos bifuncionales que contienen el farmacóforo cti |
| TWI730959B (zh) * | 2015-05-19 | 2021-06-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| EP3317269B1 (en) | 2015-07-02 | 2022-09-21 | F. Hoffmann-La Roche AG | Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases |
| AU2016340527B2 (en) | 2015-10-23 | 2020-09-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2017096301A1 (en) * | 2015-12-04 | 2017-06-08 | Denali Therapeutics Inc. | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk 1) |
| IL287136B2 (en) | 2016-02-05 | 2023-09-01 | Denali Therapeutics Inc | Receptor inhibitors - interacting with protein kinase 1 |
| CN109071409B (zh) * | 2016-03-14 | 2021-09-17 | 斯帕罗化学股份公司 | 制备取代的双环[1 1 1]戊烷的方法 |
| US10980806B2 (en) * | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| CN105785659B (zh) * | 2016-05-20 | 2018-07-10 | 深圳市华星光电技术有限公司 | 含功能化石墨烯层的液晶面板结构及功能化石墨烯膜的制备方法 |
| WO2018073193A1 (en) | 2016-10-17 | 2018-04-26 | F. Hoffmann-La Roche Ag | Bicyclic pyridone lactams and methods of use thereof |
| US11071721B2 (en) | 2016-12-02 | 2021-07-27 | Genentech, Inc. | Bicyclic amide compounds and methods of use thereof |
| KR20190087622A (ko) * | 2016-12-08 | 2019-07-24 | 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 | 질환 치료를 위한 이중 류신 지퍼 (dlk) 키나아제의 바이시클로[1.1.1]펜탄 억제제 |
| JP7208137B2 (ja) | 2016-12-09 | 2023-01-18 | デナリ セラピューティクス インコーポレイテッド | 化合物、組成物および方法 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| US20200062735A1 (en) | 2017-02-27 | 2020-02-27 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| CA3063934A1 (en) * | 2017-05-17 | 2018-11-22 | Denali Therapeutics Inc. | Kinase inhibitors and uses thereof |
| WO2019034178A1 (zh) * | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 一种dna毒性二聚体化合物 |
| IL272875B2 (en) * | 2017-09-11 | 2023-10-01 | Recurium Ip Holdings Llc | Continuous flow processes for the preparation of bicyclic compounds |
| AR114136A1 (es) * | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| EP3704125B1 (en) * | 2017-11-02 | 2026-03-11 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
| UY37956A (es) * | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| EP3494994A1 (en) | 2017-12-07 | 2019-06-12 | Universität zu Köln | Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases |
| WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| HRP20231381T1 (hr) | 2018-05-03 | 2024-03-01 | Rigel Pharmaceuticals, Inc. | Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu |
| MD3788045T2 (ro) | 2018-05-03 | 2023-09-30 | Rigel Pharmaceuticals Inc | Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora |
| WO2019224773A1 (en) * | 2018-05-23 | 2019-11-28 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors |
| WO2021046515A1 (en) | 2019-09-06 | 2021-03-11 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| IL291665B2 (en) | 2019-09-27 | 2025-07-01 | Univ Texas | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| US11560366B2 (en) * | 2019-10-21 | 2023-01-24 | Board Of Regents, The University Of Texas System | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease |
| BR112022010082A2 (pt) | 2019-11-26 | 2022-08-30 | Univ Texas | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica |
| CA3169099A1 (en) | 2020-02-28 | 2021-09-02 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
-
2020
- 2020-09-24 IL IL291665A patent/IL291665B2/en unknown
- 2020-09-25 BR BR112022005627A patent/BR112022005627A2/pt unknown
- 2020-09-25 WO PCT/US2020/052789 patent/WO2021062199A1/en not_active Ceased
- 2020-09-25 JP JP2022519289A patent/JP7802655B2/ja active Active
- 2020-09-25 CN CN202080067791.3A patent/CN115605463B/zh active Active
- 2020-09-25 US US17/033,104 patent/US11753381B2/en active Active
- 2020-09-25 MX MX2022003671A patent/MX2022003671A/es unknown
- 2020-09-25 AU AU2020353663A patent/AU2020353663B2/en active Active
- 2020-09-25 EP EP20867775.7A patent/EP4034530A4/en active Pending
- 2020-09-25 CA CA3155259A patent/CA3155259A1/en active Pending
- 2020-09-25 KR KR1020227013817A patent/KR20220072857A/ko active Pending
-
2023
- 2023-07-20 US US18/355,792 patent/US12286406B2/en active Active
-
2025
- 2025-03-18 US US19/083,018 patent/US20250214942A1/en active Pending
- 2025-06-25 JP JP2025107082A patent/JP2025138749A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022550099A5 (enExample) | ||
| DE69833224T2 (de) | Benzothiazole als protein tyrosin-kinase inhibitoren | |
| NZ599860A (en) | Carboxamide compounds and their use as calpain inhibitors | |
| IL160522A (en) | 1h - imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1-antagonistic activity | |
| ZA202201505B (en) | Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer | |
| SK286072B6 (sk) | 1,2-anelované chinolínové deriváty, spôsob ich prípravy, medziprodukty, farmaceutický prostriedok aich použitie | |
| JP2008535902A5 (enExample) | ||
| CA2493225A1 (en) | Quinoline derivatives and their use as mycobacterial inhibitors | |
| JP2004518723A5 (enExample) | ||
| RU2007146798A (ru) | ПРОИЗВОДНЫЕ 4-(2-АМИНО-1-ГИДРОКСИЭТИЛ)ФЕНОЛА КАК АГОНИСТЫ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА | |
| JP2008535903A5 (enExample) | ||
| JP2010502717A5 (enExample) | ||
| AU2007235576A1 (en) | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | |
| HUP0304054A2 (hu) | A kortikotropin-realising faktor (CRF) antagonistáiként alkalmazható kondenzált pirimidinek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| JP2008001718A5 (enExample) | ||
| IL291665B2 (en) | Inhibitors of receptor interacting protein kinase i for the treatment of disease | |
| JP2012523457A5 (enExample) | ||
| JP2013538801A5 (enExample) | ||
| JP2017511378A5 (enExample) | ||
| RU2016108038A (ru) | Новые фталазиновые производные и способ их получения | |
| US11339122B2 (en) | hTRPV1 chemical agents | |
| US20040229927A1 (en) | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | |
| JP2012507525A5 (enExample) | ||
| JP2010520168A5 (enExample) | ||
| JP2016534143A5 (enExample) |